Thomas Finley, MD
Ophthalmology · Tulsa, OKNPI 1821201088
Payments from drug & device makers
What this record shows
17 manufacturers reported payments, led by US Retina LLC at 59.6% of the total. Reporting peaked in 2022 at $2,634 and has fallen 71.0% since, to $765 in 2025. Among ophthalmology clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $76.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$5K
- Alimera Sciences, Inc.$926
- Regeneron Healthcare Solutions, Inc.$473
- AbbVie$391
- Genentech USA, Inc.$357
- Coherus Oncology, Inc.$338
- plus $1K from 11 others
What the payments were for
- Food & beverage$3,69840%
- Ownership interest$5,46160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $5,461 |
| Alimera Sciences, Inc. | 10 | $926 |
| Regeneron Healthcare Solutions, Inc. | 13 | $473 |
| AbbVie(2 entities) | 19 | $391 |
| Genentech USA, Inc. | 13 | $357 |
| Coherus Oncology, Inc. | 14 | $338 |
| Sandoz | 13 | $245 |
| Apellis Pharmaceuticals, Inc. | 6 | $245 |
| US Oncology Corporate, Inc. | 1 | $189 |
| Astellas Pharma US Inc | 6 | $144 |
| ANI Pharmaceuticals, Inc. | 3 | $100 |
| Eyepoint US, Inc. | 4 | $98 |
| Bausch & Lomb Americas Inc. | 3 | $53 |
| Genentech, Inc. | 2 | $48 |
| Alcon | 3 | $41 |
| Novartis | 2 | $35 |
| Biogen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,159 in reported general payments places this provider in the 90th percentile of 183 ophthalmology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 19 | $1,575 |
| Prednisolone Acetate | 27 | $1,399 |
| Acetazolamide | 13 | $561 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 23 | $361 |
| Timolol Maleate | 14 | $78 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Tulsa
- Shehzad BatliwalaTulsa$11K
- Jamal SiddiquiTulsa$7K
- Kelli DyerTulsa$6K
- Lars FreisbergTulsa$6K
- Neha SangalTulsa$5K
- Thomas BriggsTulsa$4K
- Marc GoldbergTulsa$4K
- Daniel LangleyTulsa$3K
- Mark AllisonTulsa$3K
- Justin ParschauerTulsa$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.